Pfizer Inc. $PFE Stake Lowered by Bridger Management LLC

Bridger Management LLC cut its stake in Pfizer Inc. (NYSE:PFE) by 12.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 408,728 shares of the biopharmaceutical company’s stock after selling 57,331 shares during the quarter. Pfizer makes up 5.8% of Bridger Management LLC’s portfolio, making the stock its 5th biggest holding. Bridger Management LLC’s holdings in Pfizer were worth $9,908,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC raised its position in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC raised its holdings in shares of Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares in the last quarter. J.W. Cole Advisors Inc. lifted its stake in shares of Pfizer by 87.0% in the 1st quarter. J.W. Cole Advisors Inc. now owns 208,645 shares of the biopharmaceutical company’s stock valued at $5,287,000 after purchasing an additional 97,092 shares during the last quarter. Teachers Retirement System of The State of Kentucky boosted its holdings in Pfizer by 4.3% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 437,753 shares of the biopharmaceutical company’s stock worth $11,093,000 after purchasing an additional 18,135 shares in the last quarter. Finally, Souders Financial Advisors increased its position in Pfizer by 11.6% during the first quarter. Souders Financial Advisors now owns 9,292 shares of the biopharmaceutical company’s stock worth $235,000 after buying an additional 964 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Bank of America increased their price objective on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Citigroup upped their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. UBS Group reiterated a “neutral” rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. The Goldman Sachs Group restated a “neutral” rating and issued a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. Finally, Morgan Stanley lowered their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating on the stock in a research note on Friday, October 10th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $28.28.

Pfizer Trading Down 0.0%

Shares of Pfizer stock opened at $25.06 on Tuesday. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $27.69. The company’s fifty day simple moving average is $24.81 and its 200-day simple moving average is $24.45. The company has a market cap of $142.47 billion, a price-to-earnings ratio of 13.33, a PEG ratio of 0.81 and a beta of 0.54. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.9%. Pfizer’s dividend payout ratio is currently 100.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.